Do you have moderate to severe ulcerative colitis?

If you are a patient with moderately to severely active ulcerative colitis and between the ages of 18 and 80, you may be eligible to participate in an investigative study that is designed to evaluate the safety and effectiveness of efavaleukin alfa on induction of clinical remission.

Patients may be eligible to participate in this study if they:

• Are between the ages of 18 and 80
• Have had a diagnosis of Moderately to Severely Active Ulcerative Colitis (UC) for 3 months or longer
• Have experienced inadequate response, loss of response, or intolerance to conventional therapy, biologic therapy, OR targeted small molecule therapy
• Do NOT have: Crohn’s disease, indeterminate colitis, UC limited to the rectum, fulminant colitis, or toxic megacolon.

Trial location: